Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLuya ChengSun Yat-sen UniversityLYLing YuanCentral South UniversityKYKe YangHunan Normal University

Discussion

Loading...

Member takes

Implication

Clinical trial demonstrates 71.4% complete response in untreated elderly DLBCL patients, highlighting safety with ongoing follow-up outcomes.

Key Points

  • This research aims to evaluate the efficacy and safety of the Pola-ZR regimen in untreated elderly DLBCL patients.
  • Conducted a phase 2 clinical trial in untreated DLBCL patients aged 60-69 or over 70 years with performance status score of 2 to 4.
  • Applied central nervous system involvement exclusion criteria and standardized treatment/follow-up procedures.
  • Primary endpoint measured was the complete response rate after 6 cycles of Pola-ZR, with secondary endpoints including safety and progression-free survival.
  • Observed a complete response rate of 71.4% after 6 cycles of Pola-ZR in evaluable patients.
  • Patients had a median progression-free survival of 18.5 months with confidence intervals provided.
  • Maintained safety profiles with manageable lung infection rates under mandatory prophylaxis for pneumocystis jirovecii pneumonia.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d63ahttps://doi.org/10.1182/blood-2025-1917
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study2025
  2. 2The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025
  3. 3Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026
  4. 4Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma2025 · 2 citations
  5. 5Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma2025